Based on the Autolus Therapeutics plc stock forecast from 0 analysts, the average analyst target price for Autolus Therapeutics plc is not available over the next 12 months. Autolus Therapeutics plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Autolus Therapeutics plc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Autolus Therapeutics plc’s stock price was EUR 2.12. Autolus Therapeutics plc’s stock price has changed by -16.54% over the past week, -21.48% over the past month and -57.43% over the last year.
No recent analyst target price found for Autolus Therapeutics plc
No recent average analyst rating found for Autolus Therapeutics plc
Company Overview Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Read Less
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational t...Read More
Frequently Asked Questions About Autolus Therapeutics plc (6A3A:F) Stock
Stock Target Advisor's fundamental analysis for Autolus Therapeutics plc's stock is Bearish.
Unfortunately we do not have enough data on 6A3A:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6A3A:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 6A3A:F's stock to indicate if its overvalued.
The last closing price of 6A3A:F's stock was EUR 2.12.
The most recent market capitalization for 6A3A:F is EUR 0.73B.
Unfortunately we do not have enough analyst data on 6A3A:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Autolus Therapeutics plc's stock.
As per our most recent records Autolus Therapeutics plc has 463 Employees.
Autolus Therapeutics plc's registered address is The Mediaworks, London, United Kingdom, W12 7FP.
You can get more information about it from Autolus Therapeutics plc's website at https://www.autolus.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Autolus Therapeutics plc (6A3A:F) Stock
Stock Target Advisor's fundamental analysis for Autolus Therapeutics plc's stock is Bearish.
Unfortunately we do not have enough data on 6A3A:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6A3A:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 6A3A:F's stock to indicate if its overvalued.
The last closing price of 6A3A:F's stock was EUR 2.12.
The most recent market capitalization for 6A3A:F is EUR 0.73B.
Unfortunately we do not have enough analyst data on 6A3A:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Autolus Therapeutics plc's stock.
As per our most recent records Autolus Therapeutics plc has 463 Employees.
Autolus Therapeutics plc's registered address is The Mediaworks, London, United Kingdom, W12 7FP.
You can get more information about it from Autolus Therapeutics plc's website at https://www.autolus.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6A3A:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
